Filing Flows › Rhythm Pharmaceuticals (RYTM) › Q2 2026 › vs Q1 2026
Rhythm Pharmaceuticals (RYTM) Q2 2026 vs Q1 2026 (quarter over quarter)
Rhythm Pharmaceuticals's revenue rose $11.1M (+19%) from $60.1M in Q1 2026 to $71.3M in Q2 2026.
Rhythm Pharmaceuticals, Q2 2026: revenue $71.3M (+47% year over year), operating margin -68.1%, net loss $49.3M, operating cash flow −$9.2M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $71.3M | $60.1M | $11.1M | +19% |
| Net loss | $49.3M | $55.6M | −$6.3M | -11% |
| Costs & expenses | $121M | $116M | $4.8M | +4% |
| Operating costs | $120M | $112M | $7.3M | +7% |
| Interest & other, net | $302K | $2.7M | −$2.4M | -89% |
| Income tax | $444K | $545K | −$101K | -19% |
| Cost of revenue | $8.9M | $7.2M | $1.8M | +25% |
| Research & development | $43.4M | $41.7M | $1.7M | +4% |
| SG&A | $67.4M | $63.6M | $3.9M | +6% |
| Operating cash sources | $49.3M | $55.6M | −$6.3M | -11% |
| Share-based compensation | $26.1M | $23.1M | $3.0M | +13% |
| Working capital & other | $14.1M | −$11.6M | $25.7M | — |
| Cash used in operations | $9.2M | $44.2M | −$35.0M | -79% |
| Net loss absorbed | $49.3M | $55.6M | −$6.3M | -11% |
Questions
How much did Rhythm Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Rhythm Pharmaceuticals's revenue rose $11.1M (+19%) from $60.1M in Q1 2026 to $71.3M in Q2 2026.